News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
746,134 Results
Type
Article (44012)
Company Profile (313)
Press Release (701791)
Multimedia
Podcasts (121)
Webinars (22)
Section
Business (211061)
Career Advice (2110)
Deals (36775)
Drug Delivery (133)
Drug Development (83480)
Employer Resources (176)
FDA (16875)
Job Trends (15517)
News (357563)
Policy (34146)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2629)
Accelerated approval (42)
Adcomms (27)
Allergies (166)
Alliances (51587)
ALS (196)
Alzheimer's disease (1760)
Antibody-drug conjugate (ADC) (377)
Approvals (17186)
Artificial intelligence (615)
Autoimmune disease (225)
Automation (50)
Bankruptcy (373)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (207)
Biotechnology (187)
Bladder cancer (177)
Brain cancer (67)
Breast cancer (694)
Cancer (5355)
Cardiovascular disease (458)
Career advice (1793)
Career pathing (39)
CAR-T (300)
CDC (56)
Celiac Disease (2)
Cell therapy (805)
Cervical cancer (41)
Clinical research (71777)
Collaboration (1935)
Company closure (4)
Compensation (1259)
Complete response letters (77)
COVID-19 (2797)
CRISPR (104)
C-suite (990)
Cystic fibrosis (152)
Data (7050)
Decentralized trials (3)
Denatured (37)
Depression (155)
Dermatology (57)
Diabetes (553)
Diagnostics (6906)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (299)
Drug pricing (210)
Drug shortages (32)
Duchenne muscular dystrophy (268)
Earnings (92754)
Editorial (62)
Employer branding (21)
Employer resources (155)
Events (121249)
Executive appointments (1054)
FDA (20306)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1618)
Gene editing (217)
Generative AI (53)
Gene therapy (670)
GLP-1 (1058)
Government (4834)
Grass and pollen (7)
Guidances (397)
Healthcare (19099)
HIV (73)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (281)
Immuno-oncology (81)
Indications (156)
Infectious disease (3110)
Inflammatory bowel disease (207)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (277)
Interviews (327)
IPO (16927)
IRA (57)
Job creations (4072)
Job search strategy (1499)
JPM (65)
Kidney cancer (18)
Labor market (92)
Layoffs (581)
Leadership (36)
Legal (8425)
Liver cancer (97)
Longevity (29)
Lung cancer (717)
Lymphoma (408)
Machine learning (53)
Management (60)
Manufacturing (933)
MASH (182)
Medical device (13929)
Medtech (14006)
Mergers & acquisitions (20997)
Metabolic disorders (1436)
mRNA (184)
Multiple sclerosis (172)
NASH (18)
Neurodegenerative disease (385)
Neuropsychiatric disorders (99)
Neuroscience (3169)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4572)
Now hiring (73)
Obesity (680)
Opinion (299)
Ovarian cancer (184)
Pain (244)
Pancreatic cancer (254)
Parkinson's disease (337)
Partnered (34)
Patents (556)
Patient recruitment (586)
Peanut (63)
People (61230)
Pharmaceutical (86)
Pharmacy benefit managers (33)
Phase 1 (22277)
Phase 2 (31571)
Phase 3 (23647)
Pipeline (7061)
Policy (318)
Postmarket research (2655)
Preclinical (9461)
Press Release (68)
Prostate cancer (275)
Psychedelics (51)
Radiopharmaceuticals (308)
Rare diseases (1016)
Real estate (6308)
Recruiting (72)
Regulatory (25831)
Reports (54)
Research institute (2454)
Resumes & cover letters (362)
Rett syndrome (32)
RNA editing (18)
RSV (85)
Schizophrenia (168)
Series A (272)
Series B (201)
Service/supplier (11)
Sickle cell disease (109)
Special edition (25)
Spinal muscular atrophy (167)
Sponsored (46)
Startups (3774)
State (2)
Stomach cancer (19)
Supply chain (118)
Tariffs (96)
The Weekly (82)
Vaccines (1082)
Venture capital (100)
Weight loss (439)
Women's health (109)
Worklife (19)
Date
Today (128)
Last 7 days (654)
Last 30 days (2845)
Last 365 days (30588)
2026 (7804)
2025 (30678)
2024 (35762)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (802)
Alabama (88)
Alaska (7)
Arizona (335)
Arkansas (15)
Asia (42376)
Australia (6786)
California (12264)
Canada (3512)
China (1255)
Colorado (522)
Connecticut (521)
Delaware (367)
Europe (91043)
Florida (1847)
Georgia (391)
Hawaii (3)
Idaho (61)
Illinois (973)
India (81)
Indiana (565)
Iowa (22)
Japan (495)
Kansas (130)
Kentucky (44)
Louisiana (40)
Maine (73)
Maryland (1487)
Massachusetts (8797)
Michigan (347)
Minnesota (675)
Mississippi (6)
Missouri (137)
Montana (33)
Nebraska (29)
Nevada (136)
New Hampshire (82)
New Jersey (3273)
New Mexico (29)
New York (3235)
North Carolina (1570)
North Dakota (8)
Northern California (6057)
Ohio (363)
Oklahoma (23)
Oregon (46)
Pennsylvania (2484)
Puerto Rico (25)
Rhode Island (50)
South America (1178)
South Carolina (75)
South Dakota (1)
Southern California (4812)
Tennessee (198)
Texas (1921)
United States (43530)
Utah (367)
Vermont (1)
Virginia (305)
Washington D.C. (80)
Washington State (987)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
746,134 Results for "satsuma pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
November 6, 2025
·
7 min read
Press Releases
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society’s 67th Annual Scientific Meeting
June 19, 2025
·
5 min read
Press Releases
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
May 1, 2025
·
9 min read
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 66th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.
June 13, 2024
·
6 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
Press Releases
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
March 31, 2026
·
1 min read
Press Releases
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
March 23, 2026
·
4 min read
Press Releases
Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. secure public reimbursement of ABILIFY ASIMTUFII®
March 4, 2026
·
6 min read
Press Releases
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering - March 18, 2026
March 18, 2026
·
4 min read
Deals
SNBL to Acquire Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.
April 16, 2023
·
10 min read
1 of 74,614
Next
